Replies to post #124153 on Cytodyn Inc (CYDY)

[GreenBioAnalyst]

Those are the mortality rates of SOC and not that of Leronlimab!

39.5% or as much as 53.8% for critically ill patients for Standard of care; and

28% mortality rate for severe.

Leronlimab's ITT in both categories will be statistically significant over the controlled/ placebo subjects, IMO.